Crosby Catherine M, Barry Michael A
Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55902, USA.
Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55902, USA; Department of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA; Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, MN 55902, USA; Department of Immunology, Mayo Clinic, Rochester, MN 55902, USA; Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55902, USA.
Virology. 2014 Aug;462-463:158-65. doi: 10.1016/j.virol.2014.05.030. Epub 2014 Jul 2.
Replication competent adenovirus (RC-Ad) vectors mediate robust transgene expression by virtue of amplifying transgenes by replication but also put patients at a risk of frank adenovirus infection. In contrast, E1-deleted replication defective Ad (RD-Ad) vectors are safer but produce substantially less transgene product. To generate a robust, but safer adenoviral vector, we created a "single cycle" adenovirus (SC-Ad) vector that replicates its genome and transgene, but that does not cause adenovirus infections by deleting the capsid cement protein IIIa in low seroprevalence adenovirus serotype 6. Ad6-ΔIIIa can be produced in IIIa-expressing cell lines. In normal cells, Ad6-ΔIIIa replicates its genome and transgene but fails to package its DNA or form mature virus. SC-Ad and RC-Ad expressed transgenes hundreds of times higher than RD-Ad in human and mouse cells in vitro and in vivo in mice. These data suggest that SC-Ads may be safer amplifying vectors for vaccine and therapeutic applications.
具有复制能力的腺病毒(RC-Ad)载体借助复制来扩增转基因,从而介导强大的转基因表达,但也使患者面临腺病毒显性感染的风险。相比之下,E1区缺失的复制缺陷型腺病毒(RD-Ad)载体更安全,但产生的转基因产物要少得多。为了构建一种强大但更安全的腺病毒载体,我们创建了一种“单周期”腺病毒(SC-Ad)载体,它能复制其基因组和转基因,但通过删除低血清流行率的腺病毒血清型6中的衣壳黏附蛋白IIIa,不会引发腺病毒感染。Ad6-ΔIIIa可在表达IIIa的细胞系中产生。在正常细胞中,Ad6-ΔIIIa能复制其基因组和转基因,但无法包装其DNA或形成成熟病毒。在体外人细胞和小鼠细胞以及小鼠体内,SC-Ad和RC-Ad表达的转基因比RD-Ad高出数百倍。这些数据表明,SC-Ad可能是用于疫苗和治疗应用的更安全的扩增载体。